Male hypogonadism associated with advanced cancer: a systematic review.
Male hypogonadism is commonly diagnosed on the basis of subphysiological concentrations of androgen hormones, and is associated with many symptoms present in advanced cancer. Androgen deficiency might be an important cause of muscle wasting in both cancer cachexia and sarcopenia. We did a systematic review of the clinical association of male hypogonadism in advanced cancer. We searched PubMed, Medline, and Embase for publications on the relation between male hypogonadism and functional status, nutritional status, body composition, symptoms, and quality of life in patients with advanced cancer. Of 381 publications identified, six original articles were included. We found no definitive association between nutritional, functional, or quality-of-life characteristics and male hypogonadism. Possible associations between male hypogonadism and weight loss, low albumin, low-body cell mass index, low-peripheral fat and muscle mass, higher inflammation, higher pain, higher opioid consumption, worse scores for anxiety, depression, and emotional and functional well-being need to be confirmed by better designed studies. There is no clear epidemiological data to indicate whether male hypogonadism is independently associated with clinical and biological sequelae of cancer cachexia, such as higher inflammation, fatigue, and body wasting. Standardised kits sensitive to low concentrations of free-testosterone or bioavailable testosterone are needed to diagnose androgen deficiency in women. A clearer epidemiology of androgen deficiencies in advanced cancer will help determine which patients should receive testosterone-replacement therapy for alleviating cancer cachexia symptoms and improving quality of life.
Vigano
Antonio
A
McGill Nutrition & Performance Laboratory, McGill University Health Centre, Montreal, Canada.
Piccioni
Melissa
M
Trutschnigg
Barbara
B
Hornby
Laura
L
Chaudhury
Prosanto
P
Kilgour
Robert
R
D002100:Cachexia / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D007006:Hypogonadism / Q000209:etiology*; D008297:Male; D009369:Neoplasms / Q000150:complications*; D009752:Nutritional Status; D011788:Quality of Life; D013739:Testosterone / Q000172:deficiency / Q000627:therapeutic use
D013739:Testosterone